e-ISSN: Pending
WASTE Journal

Browse the failure-mode index

20,217 real negative results, null findings, and replication failures · Negative / Null Result Report. Search the index →

WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record compiled from open scholarly databases; the abstract is shown in full only where the paper is openly licensed, otherwise a short excerpt under fair use. Classifications are automated and approximate.

Negative / Null Result ReportMedicine

Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer.

Harada H, Omori S, Mori K et al. · 2022 · International journal of clinical oncology

Background This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC). Methods The major inclusion criteria were…

View details →
Negative / Null Result ReportMedicine

A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment.

Kerwin E, Dorinsky P, Patel M et al. · 2022 · The Journal of asthma : official journal of the Association for the Care of Asthma

Objective To evaluate the efficacy and safety of three doses of glycopyrrolate metered dose inhaler (GP MDI) in patients with uncontrolled asthma despite treatment with inhaled corticosteroid/long-acting β 2 -agonists (ICS/LABA) with or…

View details →
Negative / Null Result ReportOpen accessMedicine

Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis.

Kirschner P, Konen FF, Axhausen F et al. · 2026 · Therapeutic advances in neurological disorders

Background B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or…

View details →
Negative / Null Result ReportOpen accessMedicine

Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results.

Cecchini M, Kwiek B, Liu-Walsh F et al. · 2026 · Dermatology and therapy

Introduction Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a high burden and unmet needs. Herein, we have assessed the efficacy and safety of JNJ-67484703, a programmed cell death protein 1 (PD-1)-agonizing/depleting…

View details →
Negative / Null Result ReportOpen accessMedicine

Transanal versus robotic total mesorectal excision for mid- and low-rectal cancer: A single-center comparative cohort of 109 patients.

Lin CL, Chen MC, Lin CY et al. · 2026 · Journal of robotic surgery

Minimally invasive total mesorectal excision (TME) for rectal cancer can be performed via transanal TME (TaTME) or robotic TME (R-TME), yet comparative evidence in predominantly non-obese Asian cohorts remains limited. We evaluated a…

View details →
Negative / Null Result ReportOpen accessMedicine

A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas.

Wilky BA, Julian KA, Maleddu A et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research

Purpose Doxorubicin is standard chemotherapy for metastatic soft tissue sarcomas (STS) but also enhances innate/adaptive immune responses by inducing immunogenic cell death. Most STS are immune "cold" tumors that do not respond to immune…

View details →
Negative / Null Result ReportOpen accessMedicine

Lurbinectedin in small cell lung cancer.

Manzo A, Sforza V, Carillio G et al. · 2022 · Frontiers in oncology

Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works…

View details →
Negative / Null Result ReportOpen accessMedicine

Does the Benefit of Thrombectomy in Large Strokes Depend on Perfusion-Diffusion Mismatch? A Large Stroke Therapy Evaluation Trial Post Hoc Analysis.

Schiphorst AT, Arquizan C, Turc G et al. · 2026 · Journal of stroke

Background and purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large…

View details →
Negative / Null Result ReportOpen accessMedicine

Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.

Levy A, Morel D, Texier M et al. · 2025 · Signal transduction and targeted therapy

Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable…

View details →
Negative / Null Result ReportOpen accessMedicine

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.

Lenz HJ, Parikh A, Spigel DR et al. · 2024 · Journal for immunotherapy of cancer

Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in…

View details →
Negative / Null Result ReportOpen accessMedicine

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

Geurts VCM, Voorwerk L, Balduzzi S et al. · 2023 · Breast (Edinburgh, Scotland)

The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes…

View details →
Negative / Null Result ReportMedicine

NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.

Rimel BJ, Enserro D, Bender DP et al. · 2024 · Cancer

Purpose This paper reports the efficacy of the poly (ADP-ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.…

View details →
Negative / Null Result ReportMedicine

Belimumab treatment of adult idiopathic inflammatory myopathy.

Marder G, Quach T, Chadha P et al. · 2024 · Rheumatology (Oxford, England)

Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV…

View details →
Negative / Null Result ReportOpen accessMedicine

A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery.

White RA, Mezzano-Robinson V, Shi Q et al. · 2025 · The oncologist

Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine…

View details →
Negative / Null Result ReportMedicine

Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency.

Raychaudhuri R, Cheng HH, Gulati R et al. · 2026 · European urology oncology

Background and objective Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…

View details →
Negative / Null Result ReportMedicine

Early worsening of diabetic retinopathy after simultaneous pancreas and kidney transplantation-Myth or reality?

Voglová B, Hladíková Z, Nemétová L et al. · 2020 · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Early worsening of diabetic retinopathy due to sudden glucose normalization is a feared complication of pancreas transplantation; however, its rate or severity has not been studied prospectively. We followed up 43 pancreas and kidney…

View details →
Negative / Null Result ReportOpen accessMedicine

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.

Breen WG, Dixon JG, Anderson SK et al. · 2025 · Neuro-oncology

Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose…

View details →
Negative / Null Result ReportMedicine

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.

Davidson TM, Lebreton CL, Hendricksen AEW et al. · 2023 · Gynecologic oncology

Background IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a fully human monoclonal antibody against IGF1R that blocks binding of…

View details →